1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Analysis of Gilead Sciences

Analysis of Gilead Sciences

  • April 2016
  • -
  • Aruvian's R'search
  • -
  • 120 pages

Based in the United States, Gilead Sciences is a global leader in the marketing and development of anti-infective drugs. The company has approved products for the treatment of Hepatitis B & C, HIV/AIDS, fungal infections and influenza.

Aruvian Research presents Analysis of Gilead Sciences. A complete and comprehensive analysis of Gilead Sciences, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Company analysis from Aruvian includes a history of Gilead Sciences, a business segment analysis of the segments Gilead Sciences operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.

A financial analysis of Gilead Sciences is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.

A SWOT Framework Analysis of Gilead Sciences completes this in-depth company analysis.

Table Of Contents

Analysis of Gilead Sciences
A. Executive Summary

B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective

C. Industry PEST Framework Analysis
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects

D. Looking at Gilead Sciences
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.3.1 Major Holders
D.3.2 Major Direct Holders
D.3.3 Top Institutional Holders
D.3.4 Top Mutual Fund Holders
D.4 Organizational Divisions
D.5 Corporate Family
D.6 Profiling the Key Executives
D.7 Products and Services

E. Gilead Sciences: Looking at Business
E.1 Business Segments
E.2 Company Strategy
E.3 Geographical Segments
E.4 Company Subsidiaries

F. Gilead Sciences: SWOT Framework Analysis
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome

G. Profiling the Competition
G.1 Bristol-Myers Squibb Co
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Enzon Pharmaceuticals Inc.
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Hemispherx BioPharma, Inc.
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis

H. Gilead Sciences: Financial Analysis
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit and Loss Statement
H.4 Ratio Analysis

I. Gilead Sciences: Future Perspective

J. Glossary of Terms

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Europe

  • October 2016
    149 pages
  • Anti-Infective  

  • Europe  


View report >

Therapy and Anti-Infective Market in Europe

  • October 2016
    149 pages
  • Therapy  


  • Europe  


View report >

Opioid and Therapy Market in the US

  • October 2016
    13 pages
  • Opioid  


  • United States  

View report >


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.